Back
ESC Premium Access

Short term effect of SGLT2 inhibitor, Dapagliflozin added on to standard therapy in decompensated heart failure patients with diabetes mellitus

Session: Fresh look at heart failure
Topic: AHF - Drug treatment
Speaker: Doctor M. Nakagaito (Toyama, JP)
Event: ESC Congress 2017

Congress Presentation

Add to my library

Like

About the speaker

Doctor Masaki Nakagaito

University of Toyama, Toyama (Japan)
0 follower

6 more presentations in this session

Do beta-blockers improve one-year survival in heart failure patients with atrial fibrillation? Results from the ESC-HF Registry

Speaker: Doctor K. Ozieranski (Warsaw, PL)

Access
Abstract
Slides
Like
Thumbnail

Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation in the PREFER in AF registry

Speaker: Associate Professor J. Siller-Matula (Vienna, AT)

Access
Abstract
Slides
Like
Thumbnail

Association between serum potassium and clinical outcomes in UK patients with heart failure

Speaker: Ms L. Qin (Gaithersburg, US)

Access
Abstract
Slides
Like
Thumbnail

Presence of micro- and macroalbuminuria and association with cardiac mechanics in type 2 diabetes

Speaker: Doctor P. Jorgensen (Hellerup, DK)

Access
Abstract
Slides
Like
Thumbnail

Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c

Speaker: Doctor D. Fitchett (Toronto, CA)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Fresh look at heart failure

Speakers: Doctor M. Nakagaito, Doctor K. Ozieranski, Associate Professor J. Siller-Matula, Ms L. Qin, Doctor P. Jorgensen...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources